{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T10:40:44Z","timestamp":1764240044831,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroimmune Pharmacol"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s11481-017-9727-8","type":"journal-article","created":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T07:33:47Z","timestamp":1485934427000},"page":"204-209","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Impact of Age and Polytherapy on Fingolimod Induced Bradycardia: a Preclinical Study"],"prefix":"10.1007","volume":"12","author":[{"given":"Christian","family":"Ritter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin K. R.","family":"Sva\u010dina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilja","family":"Bobylev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhijeet","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toni","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmar C.","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,1]]},"reference":[{"key":"9727_CR1","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(03)00622-7","volume":"3","author":"KE Andersson","year":"2004","unstructured":"Andersson KE (2004) Antimuscarinics for treatment of overactive bladder. Lancet Neurol 3:46\u201353","journal-title":"Lancet Neurol"},{"key":"9727_CR2","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/j.1464-410X.2007.07100.x","volume":"100","author":"KE Andersson","year":"2007","unstructured":"Andersson KE, Olshansky B (2007) Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations. BJU Int 100:1007\u20131014","journal-title":"BJU Int"},{"key":"9727_CR3","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1126\/science.1208248","volume":"333","author":"TI Arnon","year":"2011","unstructured":"Arnon TI, Xu Y, Lo C, Pham T, An J, Coughlin S, Dorn GW, Cyster JG (2011) GRK2-dependent S1PR1 desensitization is required for lymphocytes to overcome their attraction to blood. Science 333:1898\u20131903","journal-title":"Science"},{"key":"9727_CR4","doi-asserted-by":"crossref","first-page":"21453","DOI":"10.1074\/jbc.C200176200","volume":"277","author":"V Brinkmann","year":"2002","unstructured":"Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P, Foster CA, Zollinger M, Lynch KR (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277:21453\u201321457","journal-title":"J Biol Chem"},{"key":"9727_CR5","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1681\/ASN.V1341073","volume":"13","author":"K Budde","year":"2002","unstructured":"Budde K, Schmouder RL, Brunkhorst R, Nashan B, Lucker PW, Mayer T, Choudhury S, Skerjanec A, Kraus G, Neumayer HH (2002) First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol: JASN 13:1073\u20131083","journal-title":"J Am Soc Nephrol: JASN"},{"key":"9727_CR6","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402\u2013415","journal-title":"N Engl J Med"},{"key":"9727_CR7","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1177\/1352458506075651","volume":"13","author":"M Seze de","year":"2007","unstructured":"de Seze M, Ruffion A, Denys P, Joseph PA, Perrouin-Verbe B (2007) The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler 13:915\u2013928","journal-title":"Mult Scler"},{"key":"9727_CR8","doi-asserted-by":"crossref","first-page":"30363","DOI":"10.1074\/jbc.M804392200","volume":"283","author":"R Estrada","year":"2008","unstructured":"Estrada R, Zeng Q, Lu H, Sarojini H, Lee JF, Mathis SP, Sanchez T, Wang E, Kontos CD, Lin CY, Hla T, Haribabu B, Lee MJ (2008) Up-regulating sphingosine 1-phosphate receptor-2 signaling impairs chemotactic, wound-healing, and morphogenetic responses in senescent endothelial cells. J Biol Chem 283:30363\u201330375","journal-title":"J Biol Chem"},{"key":"9727_CR9","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1124\/jpet.103.062828","volume":"309","author":"M Forrest","year":"2004","unstructured":"Forrest M, Sun SY, Hajdu R, Bergstrom J, Card D, Doherty G, Hale J, Keohane C, Meyers C, Milligan J, Mills S, Nomura N, Rosen H, Rosenbach M, Shei GJ, Singer II, Tian M, West S, White V, Xie J, Proia RL, Mandala S (2004) Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther 309:758\u2013768","journal-title":"J Pharmacol Exp Ther"},{"key":"9727_CR10","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1136\/jnnp.2008.159178","volume":"85","author":"CJ Fowler","year":"2009","unstructured":"Fowler CJ, Panicker JN, Drake M, Harris C, Harrison SC, Kirby M, Lucas M, Macleod N, Mangnall J, North A, Porter B, Reid S, Russell N, Watkiss K, Wells M (2009) A UK consensus on the management of the bladder in multiple sclerosis. Postgrad Med J 85:552\u2013559","journal-title":"Postgrad Med J"},{"key":"9727_CR11","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00415-013-7115-8","volume":"261","author":"R Gold","year":"2014","unstructured":"Gold R, Comi G, Palace J, Siever A, Gottschalk R, Bijarnia M, von Rosenstiel P, Tomic D, Kappos L (2014) Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. J Neurol 261:267\u2013276","journal-title":"J Neurol"},{"key":"9727_CR12","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1177\/1060028014550645","volume":"48","author":"NM Jasiak","year":"2014","unstructured":"Jasiak NM, Bostwick JR (2014) Risk of QT\/QTc prolongation among newer non-SSRI antidepressants. Ann Pharmacother 48:1620\u20131628","journal-title":"Ann Pharmacother"},{"key":"9727_CR13","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1600-6143.2005.00754.x","volume":"5","author":"L Koyrakh","year":"2005","unstructured":"Koyrakh L, Roman MI, Brinkmann V, Wickman K (2005) The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg 5:529\u2013536","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg"},{"key":"9727_CR14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11010-011-1173-y","volume":"363","author":"H Lu","year":"2012","unstructured":"Lu H, Yuan H, Chen S, Huang L, Xiang H, Yang G, Deng H, Zhou J (2012) Senescent endothelial dysfunction is attributed to the up-regulation of sphingosine-1-phosphate receptor-2 in aged rats. Mol Cell Biochem 363:217\u2013224","journal-title":"Mol Cell Biochem"},{"key":"9727_CR15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.clpt.6100328","volume":"83","author":"B Olshansky","year":"2008","unstructured":"Olshansky B, Serra DB (2008) Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clin Pharmacol Ther 83:231\u2013232 author reply 233","journal-title":"Clin Pharmacol Ther"},{"key":"9727_CR16","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1146\/annurev.biochem.78.072407.103733","volume":"78","author":"H Rosen","year":"2009","unstructured":"Rosen H, Gonzalez-Cabrera PJ, Sanna MG, Brown S (2009) Sphingosine 1-phosphate receptor signaling. Annu Rev Biochem 78:743\u2013768","journal-title":"Annu Rev Biochem"},{"key":"9727_CR17","doi-asserted-by":"crossref","first-page":"13839","DOI":"10.1074\/jbc.M311743200","volume":"279","author":"MG Sanna","year":"2004","unstructured":"Sanna MG, Liao J, Jo E, Alfonso C, Ahn MY, Peterson MS, Webb B, Lefebvre S, Chun J, Gray N, Rosen H (2004) Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem 279:13839\u201313848","journal-title":"J Biol Chem"},{"key":"9727_CR18","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00345-010-0513-y","volume":"28","author":"M Schiffers","year":"2010","unstructured":"Schiffers M, Sauermann P, Schurch B, Mehnert U (2010) The effect of tolterodine 4 and 8\u00a0mg on the heart rate variability in healthy subjects. World J Urol 28:651\u2013656","journal-title":"World J Urol"},{"key":"9727_CR19","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0008-6363(00)00013-4","volume":"46","author":"A Sugiyama","year":"2000","unstructured":"Sugiyama A, Yatomi Y, Ozaki Y, Hashimoto K (2000) Sphingosine 1-phosphate induces sinus tachycardia and coronary vasoconstriction in the canine heart. Cardiovasc Res 46:119\u2013125","journal-title":"Cardiovasc Res"},{"key":"9727_CR20","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/cns.12283","volume":"20","author":"E Vanoli","year":"2014","unstructured":"Vanoli E, Pentimalli F, Botto G (2014) Vagomimetic effects of fingolimod: physiology and clinical implications. CNS Neurosci Ther 20:496\u2013502","journal-title":"CNS Neurosci Ther"},{"key":"9727_CR21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/JCP.0b013e31823fb238","volume":"32","author":"F Xue","year":"2012","unstructured":"Xue F, Strombom I, Turnbull B, Zhu S, Seeger J (2012) Treatment with duloxetine in adults and the incidence of cardiovascular events. J Clin Psychopharmacol 32:23\u201330","journal-title":"J Clin Psychopharmacol"}],"container-title":["Journal of Neuroimmune Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11481-017-9727-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11481-017-9727-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11481-017-9727-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T05:32:31Z","timestamp":1719034351000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11481-017-9727-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["9727"],"URL":"https:\/\/doi.org\/10.1007\/s11481-017-9727-8","relation":{},"ISSN":["1557-1890","1557-1904"],"issn-type":[{"type":"print","value":"1557-1890"},{"type":"electronic","value":"1557-1904"}],"subject":[],"published":{"date-parts":[[2017,2,1]]}}}